Background and Objectives A multicentre trial was set up to evaluate the performance of a new leucodepletion protocol.
Introduction
Prestorage leucoreduction is being used more and more in transfusion medicine. It has been established that leucoreduction can reduce the number of non-haemolytic febrile transfusion reactions [1] , as well as the occurrence of alloimmunization [2, 3] , in patients receiving multiple transfusions. Reduction of transfusion-transmitted disease [4] -especially cytomegalovirus (CMV ) [5, 6] -is generally also considered to be an established benefit of leucodepletion. Aside from these proven benefits, some studies have additionally suggested further potential advantages of leucoreduction, for instance, improvement in the functional quality of erythrocytes during storage [7, 8] and a slower decline of important parameters of metabolism (such as intraerythrocyte ATP and extracellular potassium levels) in filtered products, which is thought to be linked to the lower levels of contaminating enzymes released from lysed leucocytes or platelets in the filtered product [9] [10] [11] .
Currently, the level of < 1 × 10 6 white blood cells (WBCs)
per transfusion is applied as a transfusion standard in many countries [12, 13] . However, in some countries components with fewer than 5 × 10 6 WBCs per component are officially considered sufficiently leucodepleted [14] . Initially, filtration after storage with a bedside filter tended to be the predominant method [10, 15] but filtration efficacy turned out to be highly variable, even after only brief periods of storage at 4 ° C [16] . Therefore prestorage leucoreduction has rapidly become the preferred method. The majority of these prestorage filtrations, however, still take place after a certain holdperiod (e.g. overnight) and it has been observed that better leucodepletion results are obtained when red blood cells (RBCs) are filtered at lower temperatures [17] . These limitations can make prestorage filtration still relatively time-consuming and labour intensive. The aim of this study was to evaluate a new filtration approach in which RBCs, collected at high haematocrit by automated blood collection, were filtered directly during ongoing collection. The residual WBC level after filtration was the main end-point.
Materials and methods

Description of the integrated filter
r \ LS filters (HemaSure, Inc., Marlborough, MA) were integrated into the Trima disposable sets at the Gambro BCT production facilities (Lakewood, CO). The r \ LS filter medium consists of non-woven fibres set in a vented hard housing.
Description of the set and of the collection procedure
The new Trima disposable set for automated collection of platelets/ plasma/ red cells, with preattached leucoreduction filter, was used ( Fig. 1 ). RBCs were collected on Trima at an 80% target haematocrit. Prior to the collection of RBCs, the fluid pathway to the filter was opened, allowing immediate filtration from the first millilitre collected onwards. At the end of the filtration, 100 ml of SAG-M solution was added to the RBCs through the filter, thus washing out the RBCs retained in the primary bag and the filter. SAG-M was added under the action of gravity -no additional pressure of any kind was applied. The SAG-M bag and primary bags were positioned over hooks that were added to the side of Trima for this particular purpose. This permitted a standardized height difference (120 cm) for filtration. It is normal that during the filtration process air enters the filter. This occurs during each procedure at the end of filtration, before addition of SAG-M, but also frequently (in 76% of runs [18] ) at the beginning of RBC collection when the accumulated RBC volume in the collection bag ( Fig. 1 ) is filtered before Trima returns to the collect phase. During this study we took care to ensure that data collection and analysis was well controlled. However, throughout the study period every participating centre retained full freedom in the use of its apheresis equipment. This was intentional so that the study conditions would be as close as possible to the actual routine automated blood-collection conditions. The reported data therefore give a good perspective on how the new high-haematocrit filtration protocol performs in a routine setting.
Study design
A multicentre trial was set up with three blood centres. The participating centres screened and selected donors according to their own routine standard operating procedures. No specific selection criteria were observed other than the centre's routine minimum postcollection criteria (minimum postcollection haematocrit: 32%; minimum postplatelet count: 100 × 10 3 / µ l). A total of 35 -70 apheresis procedures were targeted per centre. All apheresis procedures were carried out in fixed locations. No mobile settings were involved. In centres A and C, all procedures were routine automated platelet and RBC collections, whilst in centre B plasma was also collected. All centres used the same Trima sets, which had an integrated filter, and all apheresis procedures were performed according to local and European regulations [12, 19] . With regard to product yield, centres A and B targeted 225 ml of RBC at 80% haematocrit, while centre C targeted slightly larger products of 250 ml of RBC, also at 80% haematocrit. The final average haematocrit of the RBC products after addition of SAG-M are shown in Table 1 . A summary and overview of the study characteristics are given in Table 2 . All collected products were filtered and the corresponding data were included in the study. The filters performed normally and no products had to be discarded as a result of filter malfunction. 
Hb, haemglobin; Hct, haematocrit.
Laboratory analysis
All filtered products were weighed individually. The haematocrit of each filtered product after addition of SAG-M was determined using one of three automated cell counters (Coulter EPICS-XL MCL (Beckman Coulter Inc., Fullerton, CA), Sysmex SE900 (Sysmex Corporation, Long Grove, IL), Sysmex CS (Sysmex Corporation). Likewise, a sample of the filtered product was taken immediately at the end of the procedure and after thorough mixing for the determination of residual WBC levels, which were measured using Nageotte counting in centres A and C and by flow cytometry (Coulter EPICS-XL MCL) in centre B. In the latter centre, results exceeding one cell/ µ l were double-checked by means of Nageotte counting [20] . Nageotte counting was carried out according to each centre's validated procedures. No cross-centre validations were carried out. Samples were diluted 1 : 10 in Leucoplate ( Plaxan; Fiers NV, Kuurne, Belgium), and one grid (40 lanes, 50 µ l of diluted sample) was counted. One cell observed in one grid of the Nageotte chamber corresponded to 0·2 WBCs/ µ l. When no WBCs were found, calculations were performed as if one WBC was detected. This prevented the final results from being biased towards lower than real residual levels and enabled logarithmic analysis to be carried out.
Statistical analysis
The results of the residual WBC counting were analysed after log 10 transformation [21] . As seen in the log-normal probability distribution plot (Fig. 2) , many of the observations at or below the minimum detectable level ( ± 60 000 WBCs), corresponding to a concentration of 0·2 WBCs/ µ l, result in a deviation from the straight line. These results were included in the plot but were excluded from the leastsquares fit of the regression line in order not to bias the prediction.
Results
General
A total of 147 procedures were performed in the three participating centres (58, 54 and 35 procedures in centres A, B and C, respectively). All filtrations were completed without any specific side events noted.
Blood cell count
The haematocrit and haemoglobin content of the filtered products after SAG-M addition were found to comply with the Council of Europe guidelines: 57·3 ± 3·0% and 55·1 ± 4·3 g / unit, respectively.
Yield
Yield was calculated on the basis of the above haematocrit data and the product volume determined after each filtration. The average efficiency, i.e. the percentage comparing how much actual product was obtained relative to the amount targeted by the machine, was 91·6 ± 4·3%. The efficiency achieved in each centre is shown in Table 1 . Figure 2 shows the log-normal probability plot of the total residual white cell levels of all procedures. The population is clearly log-normally distributed with a mean of 0·078 × 10 6
WBCs
WBCs per filtered unit (mean ± SD, 4·89 ± 0·45). All products showed good leucodepletion: none of the products contained > 1 × 10 6 WBCs. In 76 out of 105 (72%) Nageotte counts performed, either one or no WBCs at all were seen in the 40 lanes of the Nageotte chamber, which explains the deviation from a straight line below this detection limit. Regression analysis of the linear part of the log-normal probability plot indicates that 99·3% of the procedures can be expected to contain < 1 × 10 6 WBC. The median residual WBC level was 0·06 × 10 6 per product with a minimum of 0·03 × 10 6 and a maximum of 0·75 × 10 6 WBCs. 
Discussion
This report describes the quantitative aspects of the RBC components obtained after automated blood collection and filtration at high haematocrit. SAG-M is only added after filtration is finished, via the primary bag and through the leucodepletion filter, thus rinsing out a proportion of the remaining RBCs. This latter stage might appear contrary to commonly recognized principles of filtration because of the expected risk of washing out the captured WBCs. Even though evaluation of this aspect was not part of the study protocol and hence not quantified, it can be affirmed that the rinsing at least did not cause the products to exceed standards. Starting filtration during the automated blood collection results in a final, leucodepleted RBC product shortly after the apheresis procedure is completed. The results of this study also show very good leucodepletion characteristics and demonstrate that filtration at high haematocrit offers an efficient and reproducible way of leucodepleting RBC products. Residual WBCs in all filtered products remained well below the 1 × 10 6 limit per unit, and more than half of the products were even found to contain fewer than 1 × 10 5 WBCs per unit. Efficiency, expressed as the percentage of the measured yield over the targeted yield, was very good and resulted in more than 90% recovery of the RBC product. The recovery reported here is probably underestimated. As the prefiltration product never actually exists as a whole product (a proportion has already been filtered while the product is still being collected), no accurate prefiltration product can be established. The product targeted by the Trima was used in the recovery calculations as a prefiltration dose. Previous observations in Europe [22] have shown that the actual doses collected by Trima tend to be a few per cent below the targeted dose expressed as absolute RBC volume. This might be related to differences between haematocrits obtained through centrifuged methodology vs. impedance automatic counters [23] . In another study [24] , where more careful attempts were used to estimate the prefiltration dose, recoveries were found to be ≈ 97%. A recent study [18] has demonstrated normal storage of RBCs using the same filtration and collection approach.
In conclusion, the high-haematocrit filtration protocol evaluated in the present study has proven to be a reliable and efficient WBC-reduction system that allows centres to leucodeplete RBC products in a systematic and rapid manner whilst consistently retaining high-quality results. It complements the versatility of the automated blood collection process where products at the end of the procedure no longer require further processing. 0·06  0·12  0·03  88  B  0·15  0·75  0·03  26  C  0·06  0·46  0·06  54  A + B + C  0·06  0·75  0·03  57 
